問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Otolaryngology

Division of Hematology & Oncology

更新時間：2024-06-04

楊慕華Yang, Muh-Hwa
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

80Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊慕華

List

128Cases

2025-08-01 - 2027-11-08

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-06-01 - 2028-10-22

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-03-25 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-11-01 - 2027-03-20

Phase I/II

Active
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

  • Condition/Disease

    Advanced MTAP-null Solid Tumors

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

2024-05-15 - 2030-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-05-01 - 2028-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-08-31 - 2031-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-11-01 - 2026-10-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2025-09-01 - 2030-06-30

Phase II

Active
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection Condensed Powder

Participate Sites
7Sites

Recruiting7Sites

2022-11-30 - 2027-03-31

Phase I/II

Completed
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    注射劑 注射液

Participate Sites
4Sites

Recruiting4Sites

1 4 5 6 7 8 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB